Gillian;
I am so sorry you are going through this terrible time. Are you taking herceptin along with your chemo? Has your oncologist thought of lapatinib? I have heard that it can be used in combination with herceptin. Lolly posted the following list of excerpts from articles which you might find of interest. I have not had lung mets but many others have and will post here their experience and advice. Hang in there. I will pray for you.
Cathya
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
http://cancerres.aacrjournals.org/c...tract/66/3/1630
“…For the combination of lapatinib plus trastuzumab, synergistic drug interactions were
observed in four different HER-2-overexpressing cell lines. Moreover, lapatinib retained significant in vitro activity against cell lines selected for long-term outgrowth (>9 months) in trastuzumab-containing (100 µg/mL) culture medium. These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab. (Cancer Res 2006; 66(3): 1630-9)
Lapatinib shows 35% response in advanced breast cancer patients in initial trial of the drug as first-line treatment
http://www.medicalnewstoday.com/med...hp?newsid=24445
Main Category: Breast Cancer News
Article Date: 15 May 2005 - 15:00pm (UK)
“…The most frequently reported adverse events in this trial have been mild to moderate itching, rash, diarrhea, acne, and dry skin. No adverse events deemed drug-related, including cardiotoxicity, have been serious enough to be categorised as Grade 3 or 4 by standard toxicity criteria.
...At the San Antonio Breast Cancer Conference last December, it was reported that 6 of 26 patients (23 percent) whose cancer progressed during Herceptin treatment later experienced partial or complete responses when lapatinib was added to their standard Herceptin regimen...
Lapatinib has been granted fast-track status by the FDA for the treatment of refractory advanced or metastatic breast cancer who have documented ErbB2 overexpression and who have failed previous therapy, including Herceptin…”
Breakthroughs in Breast Cancer Treatments
http://www.webmd.com/content/pages/24/113001.htm
“…Findings about an experimental oral drug, lapatinib, were also presented at the meeting. Like Herceptin, lapatinib targets HER2, but it also targets a related protein called EGFR, meaning that it could have a broader range of effectiveness or could be especially effective when added to Herceptin. One small study evaluated the combination of lapatinib and Herceptin in patients with metastatic breast cancer. The researchers reported no additional or unexpected side effects with the combination. Moreover, a good percentage of this difficult-to-treat population responded to the treatment.
"We are very excited about the results of all of these studies with these new agents, and they clearly demonstrate a role for this type of therapy in the treatment of metastatic breast cancer," Miller says. "We also expect an even greater benefit for these therapies when used for earlier-stage disease as opposed to the metastatic setting."
Published Jan. 30, 2006.
--------------------------------------------------------------------------------